Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Lichtman SM, Niedzwiecki D, Barcos M, Carlisle TL, Cooper MR, Johnson JL, Peterson BA. Lichtman SM, et al. Among authors: niedzwiecki d. Ann Oncol. 2000 Sep;11(9):1141-6. doi: 10.1023/a:1008395400069. Ann Oncol. 2000. PMID: 11061609 Free article. Clinical Trial.
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG; Cancer and Leukemia Group B. Roberts JD, et al. Among authors: niedzwiecki d. J Immunother. 2006 Jan-Feb;29(1):95-101. doi: 10.1097/01.cji.0000195295.74104.ad. J Immunother. 2006. PMID: 16365605 Clinical Trial.
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, Peterson BA, Byrd JC, Cheson BD; Cancer and Leukemia Group B Study 9153. Blum KA, et al. Among authors: niedzwiecki d. Cancer. 2006 Dec 15;107(12):2817-25. doi: 10.1002/cncr.22344. Cancer. 2006. PMID: 17120198 Free article. Clinical Trial.
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD; Cancer and Leukemia Group B. Smith SM, et al. Among authors: niedzwiecki d. Br J Haematol. 2008 Feb;140(3):313-9. doi: 10.1111/j.1365-2141.2007.06937.x. Br J Haematol. 2008. PMID: 18217897 Free article. Clinical Trial.
330 results